Fosun Pharma signs Sandoz deal and gives Fosun Pharma stock USD 237 million context

Published on 10/13/2026 at 00:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sandoz may pay up to USD 237.00 million for three biosimilar products. Fosun Pharma stock has results due October 28, 2026.

Key points in brief

Fosun Pharma signed an October 8, 2026 licensing framework with Sandoz covering up to 10 biosimilar products.
Sandoz may pay up to USD 237.00 million for the first three products, plus up to USD 77.00 million in sales milestones.
Six-month 2026 revenue reached CNY 20.38 billion, up 4.90 percent year over year, while innovative-drug revenue rose 13.80 percent.
The last Lang & Schwarz price was EUR 1.97 on October 12, 2026.

Fosun Pharma, CNE100001M79, Illustration mit AI erstellt.

Fosun Pharma (CNE100001M79) had signed a licensing framework with Sandoz on October 8, 2026, covering up to 10 biosimilar products. As GMT EIGHT reported, Sandoz may pay up to USD 237.00 million in upfront payments, development milestones and development budget milestone payments for the first three products.

What the deal means for revenue

The agreement also includes up to USD 77.00 million in sales milestone payments and a 40 percent share of net sales or net profit, while Sandoz paid an USD 8.00 million option fee for one potential product, according to GMT EIGHT.

The commercial terms add a measurable internationalization angle to Fosun Pharma's pipeline. The company operates in pharmaceutical manufacturing, medical devices, diagnostics and healthcare services, according to its investor-relations profile.

Three dated milestones shape the story

On June 30, 2026, Fosun Pharma reported six-month revenue of CNY 20.38 billion, up 4.90 percent year over year, and innovative-drug revenue of CNY 4.91 billion, up 13.80 percent, in an interim report carried by Futu.

On September 14, 2026, a Fosun Pharma application for HLX14 was accepted by a Chinese drug regulator, as reported by MarketScreener. On October 8, 2026, the Sandoz framework followed with terms covering up to 10 products and USD 237.00 million for the first three.

What does the pipeline add?

The interim report showed that overseas business revenue rose 16.50 percent year over year in the six months ended June 30, 2026, while research and development investment increased 25.70 percent to CNY 3.25 billion, according to Futu. Those figures frame the Sandoz agreement as a potential commercialization channel rather than a standalone earnings result.

Next date for Fosun Pharma stock

Fosun Pharma is scheduled to report third-quarter 2026 results on October 28, 2026, according to Simply Wall St. That date will provide the next reported update on revenue, profitability and product development.

Last euro quote before publication

The last available Lang & Schwarz quote stood at EUR 1.97 on October 12, 2026 at 10:57 p.m. CEST. The primary listing for the H shares is HKEX under ticker 02196.

The further course of trading is shown by the continuously updated real-time quote of Fosun Pharma stock.